| 0.2322 -0.129 (-35.77%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.9  |
1-year : | 1.3 |
| Resists | First : | 0.77 |
Second : | 1.11 |
| Pivot price | 0.46 |
|||
| Supports | First : | 0.23 |
Second : | 0.19 |
| MAs | MA(5) : | 0.35 |
MA(20) : | 0.55 |
| MA(100) : | 0.93 |
MA(250) : | 2.36 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 1.1 |
D(3) : | 2.4 |
| RSI | RSI(14): 24.3 |
|||
| 52-week | High : | 9 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LNAI ] has closed above bottom band by 4.6%. Bollinger Bands are 22.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.36 - 0.36 | 0.36 - 0.36 |
| Low: | 0.23 - 0.23 | 0.23 - 0.23 |
| Close: | 0.23 - 0.23 | 0.23 - 0.23 |
A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.
Thu, 05 Mar 2026
Lunai Bioworks initiates employee furloughs and salary deferrals to preserve liquidity - Investing.com UK
Thu, 05 Mar 2026
Lunai Bioworks implements temporary furloughs, execs defer salaries to preserve liquidity - TradingView
Thu, 19 Feb 2026
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping - Yahoo Finance
Fri, 13 Feb 2026
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC - Nasdaq
Fri, 13 Feb 2026
AI that hunts new drugs and bio threats: inside Lunai’s CNBC spotlight - Stock Titan
Mon, 09 Feb 2026
Lunai Bioworks (Nasdaq Lnai) Launches Ai Oncology Pilot - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 38.2 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 287 (K) |
| Shares Short P.Month | 553 (K) |
| EPS | -7.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13.4 % |
| Return on Equity (ttm) | -366.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | -0.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|